Routine RSU scheme administration — no trading signal. Monitor upcoming quarterly results for pipeline progress on olverembatinib and lisaftoclax, which are the primary value drivers.
Price Chart
Executive Summary
Ascentage Pharma disclosed that its trustee purchased 200,000 existing shares on-market for ~HK$5.74 million (avg ~HK$28.70/share) to satisfy RSU vesting under the 2022 RSU Scheme. This is a routine administrative step to fund equity compensation — no new capital raised, no change in fundamentals, and no signal of management's view on valuation.
Key Facts
- Trustee purchased 200,000 existing shares on-market on October 22, 2026.
- Total consideration was HK$5,740,622 (approx. HK$28.70 per share).
- Purchased shares represent ~0.05% of total issued shares.
- Total shares held by trustee under the 2022 RSU Scheme now 3,115,000 shares.
- No new grant of awards was made — only share purchases to satisfy prior vesting obligations.
Financial Impact
HK$5.74 million in open-market purchases, representing ~0.05% of outstanding shares — immaterial relative to market cap.
Risk Factors
- No material risk identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111727 |
| Document: ea0309432-6k_ascentage.htm | 0001213900-26-111727 |
| Document: 0001213900-26-111727-index-headers.html | 0001213900-26-111727 |
| Document: 0001213900-26-111727-index.html | 0001213900-26-111727 |
| Document: 0001213900-26-111727.txt | 0001213900-26-111727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.45 (+3.55%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.45 (+3.55%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.45 (+5.17%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.45 (−0.52%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.45 (+10.80%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.45 (−8.34%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.45 (−8.06%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.45 (−18.21%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.45 (−15.90%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.45 (−19.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers